Cftr Trikafta denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Quantity Limits to Trikafta

Quantity limit (QL) denials occur when a prescription is written for a supply amount — number of tablets, days' supply, or package count — that exceeds what BCBS's formulary allows per fill or per defined time period. For a maintenance therapy like this CFTR modulator combination, quantity limit denials often arise from discrepancies between the prescriber's intended dosing schedule and the plan's default dispensing parameters. These denials are frequently resolved by clarifying the prescribed regimen or by requesting a quantity limit exception.

## Your Federal Appeal Rights

A quantity limit denial is an adverse benefit determination. Under ACA §2719 and ERISA §503, you have the right to internal appeal and, if denied, external independent review. You typically have 180 days from the denial to file an internal appeal and four months after an internal denial to request external review. Expedited review is available when a delay in medication would jeopardize health.

## The Concrete Appeal Process

1. Clarify the precise quantity being denied — ask BCBS exactly what quantity it will cover and what the prescription requested. Sometimes a discrepancy is a simple pharmacy entry error. 2. Request a quantity limit exception through the prescriber's office — this is often a faster path than a formal grievance appeal. 3. If the exception is denied, file a formal internal appeal with a prescriber letter explaining the medical necessity of the prescribed quantity per the FDA-approved dosing regimen. 4. If denied internally, escalate to independent external review.

## Documentation to Gather

• Prescriber letter confirming the prescribed quantity matches the FDA-approved dosing regimen as described in the current prescribing label — this is the central argument for quantity limit overrides
• FDA prescribing label with the relevant dosing section highlighted
• Pharmacy dispensing records showing what was prescribed and what the plan covered
• Clinical notes documenting that the patient is established on this therapy and the rationale for the prescribed supply
• If requesting an extended days' supply (e.g., 90-day): documentation of clinical stability and patient's geographic or logistical circumstances if relevant

## Criteria-Mapping Structure

Obtain BCBS's quantity limit criteria for this drug. Then map:

| Quantity Limit Parameter | Patient Prescription Detail | |---|---| | Maximum units per fill (plan limit) | Compare to prescribed quantity — document any match or explain discrepancy | | FDA-approved dosing frequency | Label excerpt confirming regimen | | Clinical necessity of prescribed quantity | Prescriber attestation letter | | Continuity-of-therapy rationale (if 90-day) | Chart notes confirming stable, established regimen |

The core legal argument is that the plan may not impose quantity limits that are inconsistent with the FDA-approved dosing regimen when the prescriber has documented medical necessity for that regimen. Cite this principle explicitly in the appeal letter.